Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Celgene International Sarl (CELG) has announced positive results of phase I/II clinical trial assessing the efficacy of Abraxane Clinical Potential in patients with advanced pancreatic cancer.
Subscribe to our email newsletter
Abraxane, developed using nab technology platform, is a solvent-free chemotherapy treatment option for metastatic breast cancer.
The study comprised evaluation of Abraxane in combination with gemcitabine in 67 patients.
Abraxane with gemcitabine demonstrated a median overall survival of 12.2 months
The levels of secreted protein acidic and rich in crysteine (SPARC) were evaluated in 36 patients and patients with high-SPARC biomarker achieved higher overall survival.
The data is published in Journal of Clinical Oncology Online.